Scioto Biosciences, an Indianapolis-based preclinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, closed on $1.8M in Series A financing.
Backers included BioCrossroads, Elevate Ventures, Rev1 Ventures.
The company intends to use the funds to launch of its new microbiome platform technology.
Founded in May 2017 and led by Joe Trebley, CEO, Scioto Biosciences is developing a microbiome therapeutics platform which has the potential to enhance efficacy wherever probiotics are used such as diabetes, neurological disorders, gastrointestinal health, alternatives to in-feed antibiotics (in livestock) and others.
Key people also include Gail Besner, Chief of Pediatric Surgery at Nationwide Children’s Hospital, co-inventor and co-founder, and Steve Goodman, Associate Professor of Pediatrics at Nationwide Children’s Hospital and also co-inventor and co-founder of Scioto.